Drug intelligence / Profile preview

Shenling Fukang granule

Development stage: Unknown
Lead developer: 湖南省中医药研究院附属医院
Administration: Oral

Overview

Shenling Fukang granule is a Traditional Chinese Medicine (TCM) formulation developed by The Affiliated Hospital of Hunan Academy of Chinese Medicine. It is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled clinical trial (ChiCTR2400080348) for the treatment of post-acute sequelae of SARS-CoV-2 infection (PASC), commonly referred to as Long COVID. The granule is designed to support patients during the recovery period following a COVID-19 infection, likely by addressing symptoms such as fatigue and respiratory weakness through TCM principles of tonifying Qi and strengthening the spleen.

Other names: Shenling Fukang Keli

Beyond the preview

Go deeper on Shenling Fukang granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenling Fukang granule.

Explore the full profile